drugset / Trial / NCT01636908
Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
NaSingle-groupOpen-labelDiagnostic
Summary
The purpose of this study is to determine intratumoral concentration of kinase inhibitors upon 2 weeks of treatment in tumor tissue of patients.
Timeline
- Start
- 2011-08
- Primary completion
- 2018-01-01
- Completion
- 2019-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | 150 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | Lapatinib | Small molecule | 1250 mg | Oral |
| Subject | Pazopanib | Small molecule | 800 mg | Oral |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |
| Subject | Sunitinib | Small molecule | 50 mg | Oral |
| Subject | Vemurafenib | Small molecule | 960 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |